Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
RenovoRx, Inc. reports news on targeted oncology drug delivery, the commercialization of RenovoCath®, and clinical development of its TAMP™ therapy platform. The company is a life-sciences issuer developing localized cancer therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device used for temporary vessel occlusion and chemotherapeutic drug infusion.
Recurring updates cover RenovoCath adoption at U.S. cancer centers, intellectual-property protection for the device, financing activity, financial results, and presentations of clinical or pharmacologic data. News also tracks IAG, the investigational intra-arterial gemcitabine product candidate delivered via RenovoCath, including disclosures tied to the TIGeR-PaC trial in locally advanced pancreatic cancer and orphan drug designations for pancreatic and bile duct cancer.
RenovoRx (Nasdaq: RNXT) received FDA Orphan Drug Designation for intra-arterial oxaliplatin to treat pancreatic cancer, its third ODD and second in pancreatic cancer.
Benefits include seven years of potential market exclusivity, a 25% clinical research tax credit, FDA fee waiver, and grant eligibility. The TIGeR-PaC Phase III trial continues, with enrollment closure expected June 2026 and final data in mid–late 2027.
RenovoRx (Nasdaq: RNXT) reported pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, published for the 2026 ASCO Annual Meeting.
The sub-study evaluates the TAMP platform delivering intra-arterial gemcitabine via RenovoCath (IAG) in 16 patients across six sites, suggesting reduced systemic gemcitabine exposure, increased inactive metabolite levels, and a correlation with reduced CA 19-9, potentially supporting higher local potency and fewer systemic side effects versus IV gemcitabine.
RenovoRx (Nasdaq: RNXT) will present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20, 2026. CEO Shaun Bagai and CFO Mark Voll will discuss record Q1 2026 RenovoCath revenue, device adoption, repeat orders, and key clinical programs.
They will review the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, expected enrollment completion by end of June 2026 and final data mid to late 2027, plus investigator-initiated and registry studies.
RenovoRx (Nasdaq: RNXT) reported record Q1 2026 revenue of $563,000, up 136% quarter-over-quarter and exceeding 50% of full-year 2025 revenue. Active commercial cancer centers increased to 16, with 32 more in the pipeline.
Cash totaled $12.4 million, supported by a $10 million private placement, which the company believes funds operations into at least the second half of 2027. The Phase III TIGeR-PaC trial is 93% enrolled, with full enrollment expected by June 2026 and final data anticipated in mid to late 2027. Net loss was $3.5 million, and RenovoRx reiterated 2026 revenue guidance of $3–$4 million.
RenovoRx (Nasdaq: RNXT) will host its First Quarter 2026 financial results and business highlights conference call on May 14, 2026 at 4:30 pm ET. Management will discuss commercial momentum for RenovoCath, repeat orders, and updates on the Phase III TIGeR-PaC trial nearing full enrollment and on track for completion in H1 2026.
A replay will be available through May 28, 2026, and webcast details are on the company's Investor Relations site.
RenovoRx (Nasdaq: RNXT) announced that a pharmacokinetic and pharmacodynamic sub‑study from its Phase III TIGeR‑PaC trial was accepted for presentation at the 2026 ASCO Annual Meeting.
The abstract (E16463) compares intra‑arterial gemcitabine via RenovoCath (IAG) with IV gemcitabine, examining systemic drug/metabolite levels and correlation with CA 19‑9. Online publication is scheduled for May 21, 2026 at 5:00 PM ET, and the meeting runs May 29–June 2, 2026 in Chicago.
RenovoRx (Nasdaq: RNXT) presented clinical imaging data at the 2026 SIR meeting showing the TAMP therapy platform enables localized intra-arterial delivery of gemcitabine for locally advanced pancreatic cancer (LAPC).
Post-treatment FDG PET/CT showed dramatic reductions in tumor metabolic activity after eight cycles over two months, suggesting potential treatment response with reduced systemic toxicity and earlier detection of effect versus anatomy.
RenovoRx (Nasdaq: RNXT) announced a Notice of Allowance from the Japan Patent Office for a patent titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum,” strengthening protection for its RenovoCath dual-occlusion catheter and its Trans-Arterial Micro-Perfusion (TAMP) platform.
The allowed claims cover integrated imaging and pressure-sensing features for targeted infusion via the vasa vasorum; the company now reports 19 issued/allowed patents and 14 pending patents globally and is commercializing RenovoCath in the United States.
RenovoRx (Nasdaq: RNXT) was named one of Fast Company's World's Most Innovative Companies 2026, ranking #10 in the medical device category on April 1, 2026. The company highlights its FDA-cleared RenovoCath device and TAMP™ platform for targeted intra-arterial cancer therapy.
RenovoRx reported that 2025 was its first full year of revenue following the commercial launch of RenovoCath, and it estimates an initial U.S. peak annual device opportunity of ~$400 million, with multi-billion-dollar potential as indications expand.
RenovoRx (Nasdaq: RNXT) reported full-year 2025 results and a business update. RenovoCath generated $1.1 million in 2025 revenue. The company closed a private placement on March 20, 2026, raising $10 million gross (net $9.2 million) and has approximately $13 million cash on hand.
Clinical: Phase III TIGeR-PaC is on track with 104 randomized and 72 events; protocol requires 114 randomizations and 86 events for final analysis, with enrollment expected by mid-2026 and full data anticipated in 2027.